MedTrace Logo

Vitamin D3 in Systemic Lupus Erythematosus

NCT00710021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-04-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.

Conditions

Interventions

DRUG

Vitamin D3

8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight

DRUG

Vitamin D3 placebo

86% microcrystalline cellulose, 14% fumed silica by weight

Sponsors & Collaborators

  • Autoimmunity Centers of Excellence

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Cynthia Aranow, MD · Northwell Health

  • Diane Kamen, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-07-31
Completion
2011-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710021 on ClinicalTrials.gov